Empirical shielding design data for facilities administering I131 for thyroid carcinoma

Area of Science:

• Nuclear Medicine
• Radiation Oncology
• Medical Physics

Background:

• Thyroid carcinoma is a common endocrine malignancy.
• Radioactive iodine (I131) therapy is a standard treatment for thyroid cancer.
• Managing patient radiation dose is crucial for safe I131 therapy.

Purpose of the Study:

• To analyze patient discharge criteria after I131 therapy.
• To establish effective shielding design for radioiodine therapy suites.
• To optimize radiation safety protocols in nuclear medicine facilities.

Main Methods:

• Retrospective review of 434 post-thyroidectomy patients treated with I131.
• Measurement of external radiation dose rates at 1 meter from patients.
• Calculation of effective design dose rates considering patient size and scatter.
• Evaluation of concrete shielding for therapy suites.

Main Results:

• Approximately 75% of patients discharged within 48 hours, 90% within 72 hours.
• Discharge criterion: external radiation dose < 25 μSv/hr at 1 meter.
• Typical time-averaged dose rate: 72 μSv/hr; 90% of patients < 82 μSv/hr.
• Recommended shielding: 190 mm concrete block walls, 150 mm concrete floors.

Conclusions:

• Rapid discharge is feasible for most I131-treated thyroid cancer patients.
• Specific shielding recommendations ensure safety for therapy suite design.
• Effective radiation dose management is key to successful I131 therapy implementation.